A COST EFFECTIVE BIOSIMILARS PLATFORM
NeuMAX® Technology Overview
NeuClone has world leading expertise in the upstream development of biosimilars including analytics and cell biology expertise to confirm biosimilarity. With this experience, NeuClone has developed the NeuMAX® platform as a part of its Right from the Start approach to making biosimilars.
NeuMAX® is an integrated CHO cell-based platform for commercial scale manufacture of complex biologics, including monoclonal antibodies and other protein drugs. The platform comprises a complementary portfolio of technologies that enhance CHO cell production of protein drugs, with major manufacturing advantages.
The system includes:
- NeuCHO® – a robust and enhanced CHO cell line with superior viability and growth characteristics;
- pNeu® -Vectors – optimised expression vectors, designed for enhanced expression, complementary to NeuCHO® cells;
- NeuGRO® – a low cost, chemically defined and animal component-free medium formulation designed to complement NeuCHO® cell lines.